Combined, these data suggest that the optimal time window for anti-amyloid intervention is likely within the first decade of PET-measured A+, and within the first five years of plasma p-tau217 positivity, before measurable tau deposition occurs and before measurable cognitive deficits occur. Here, MAPT is linked to Cognitive impairment.